SCHEMBL173322

SCHEMBL173322

CCC(CC)(CC)C(=O)O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR3 O14843 2/20 0.41
ALDH1A1 P00352 5/20 0.39
TSHR P16473 3/20 0.39
MEN1 O00255 2/20 0.39
CYP1A2 P05177 2/20 0.39
KMT2A Q03164 2/20 0.39
THRB P10828 1/20 0.39
CYP2D6 P10635 1/20 0.36
CYP2C19 P33261 1/20 0.36
HIF1A Q16665 1/20 0.36
HDAC3 O15379 1/20 0.35
HDAC1 Q13547 1/20 0.35
HDAC2 Q92769 1/20 0.35
HDAC8 Q9BY41 1/20 0.35
TDP1 Q9NUW8 2/20 0.33
CYP4F2 P78329 1/20 0.33
CYP4A11 Q02928 1/20 0.33
GRM2 Q14416 1/20 0.33
GRM3 Q14832 1/20 0.33
TP53 P04637 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6818431 0.97 FFAR3 (0.39) FFAR3ALDH1A1TSHRMEN1CYP1A2
SCHEMBL27684861 0.97 FFAR3 (0.39) FFAR3ALDH1A1TSHRMEN1CYP1A2
Hydrochloric Acid SCHEMBL8901931 0.97 FFAR3 (0.39) FFAR3ALDH1A1TSHRMEN1CYP1A2
Ammonia Solution, Strong SCHEMBL9700926 0.97 FFAR3 (0.39) FFAR3ALDH1A1TSHRMEN1CYP1A2
SCHEMBL28210395 0.97 FFAR3 (0.39) FFAR3ALDH1A1TSHRMEN1CYP1A2
SCHEMBL27899335 0.97 FFAR3 (0.39) FFAR3ALDH1A1TSHRMEN1CYP1A2
SCHEMBL27653904 0.94 FFAR3 (0.37) FFAR3ALDH1A1TSHRMEN1CYP1A2
Benzene SCHEMBL27373724 0.91 FFAR3 (0.35) FFAR3ALDH1A1TSHRMEN1CYP1A2
Ethylene Glycol SCHEMBL28513966 0.91 CYP4F2 (0.39) FFAR3ALDH1A1TSHRMEN1CYP1A2
Tetramethylammonium Ion SCHEMBL27703784 0.91 FFAR3 (0.35) FFAR3ALDH1A1TSHRMEN1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1664 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12540253-B2 Conductive ink compositions Electroninks Incorporated (US) 2026-02-03 US claimed
CN-118948649-A Emulsified perfume of non-alcohol system and preparation method thereof 中山中研化妆品有限公司 2024-11-15 CN claimed
CN-118406391-A High-dispersity spherical silicon dioxide surface grafting modification method 瑞智博(湖州)新材料科技有限公司 2024-07-30 CN claimed
WO-2024066643-A1 SUN-SCREENING COMPOSITION AND USE THEREOF 广东粤港澳大湾区黄埔材料研究院 2024-04-04 WO claimed
CN-117462490-A Amorolfine liniment 江苏知原药业股份有限公司 2024-01-30 CN claimed
EP-3694900-B1 NON-AQUEOUS CROSSLINKABLE COMPOSITION ALLNEX NETHERLANDS BV (NL) 2024-01-24 EP claimed
CN-114479716-B Environment-friendly modified polymer hot-melt pressure-sensitive adhesive and processing technology thereof 广东友华新材料科技有限公司 2023-07-25 CN claimed
CN-116422159-A High-performance CPVC anti-pollution ultrafiltration membrane spinning preparation process 天津开创膜科技有限公司 2023-07-14 CN claimed
US-11572431-B2 Non-aqueous crosslinkable composition ALLNEX NETHERLANDS B.V. (NL) 2023-02-07 US claimed
CN-115246935-A Light high-temperature-resistant plastic and preparation method thereof 王芳 2022-10-28 CN claimed
EP-0969869-A2 COMPOSITIONS COMPRISING AN INDUCING AGENT AND AN ANTI-VIRAL AGENT FOR THE TREATMENT OF BLOOD, VIRAL AND CELLULAR DISORDERS Perrine, Susan P. (US) 2000-01-12 EP claimed
WO-1999040883-A2 COMPOSITIONS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS FALLER DOUGLAS V (US) 1999-08-19 WO claimed
US-5939456-A METHOD OF STIMULATING THE EXPRESSION OF A GLOBIN PROTEIN, OR THE PROLIFERATION OR DEVELOPMENT OF ERYTHROID CELLS, MYELOID CELLS OR MEGAKARYOCYTIC CELLS FOR TREATING A DISORDER SELECTED FROM THE GROUP CONSISTING OF CYTOPENIA, AN ANEMIA AND NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 1999-08-17 US claimed
WO-1998004290-A2 COMPOSITIONS COMPRISING AN INDUCING AGENT AND AN ANTI-VIRAL AGENT FOR THE TREATMENT OF BLOOD, VIRAL AND CELLULAR DISORDERS PERRINE SUSAN P (US) 1998-02-05 WO claimed
EP-0669130-B1 Tabletting process CERESTAR HOLDING BV (NL) 1997-11-05 EP claimed
EP-0669130-A1 Tabletting process CERESTAR HOLDING BV (NL) 1995-08-30 EP claimed
EP-0222157-B1 RESIN COMPOSITION DAINIPPON INK AND CHEMICALS, INC. (JP) 1992-12-30 EP claimed
US-5117022-A Antitumor THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 1992-05-26 US claimed
WO-1990002131-A1 HYDROPHOBIC CIS-PLATINUM COMPLEXES EFFICIENTLY INCORPORATED INTO LIPOSOMES BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 1990-03-08 WO claimed
US-4058539-A 4,6,8(14)-Triene steroids STEELE CHEMICALS CO. LTD. (CA) 1977-11-15 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12540253-B2 Conductive ink compositions KCNN1, KCNN2, HCN4 FFAR3 4406/4885ALDH1A1 2220/4885TSHR 2979/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.